- Home
- EWTX vs SIG Comparison
EWTX vs SIG Comparison
Compare EWTX & SIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWTX | SIG |
|---|---|---|
| Founded | 2017 | 1950 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | EWTX | SIG |
|---|---|---|
| Price | $32.43 | $81.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $39.00 | ★ $111.14 |
| AVG Volume (30 Days) | ★ 1.2M | 669.2K |
| Earning Date | 05-07-2026 | 06-02-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | N/A | ★ 974.07 |
| EPS | N/A | ★ 7.08 |
| Revenue | N/A | ★ $6,247,100,000.00 |
| Revenue This Year | N/A | $1.39 |
| Revenue Next Year | N/A | $1.71 |
| P/E Ratio | ★ N/A | $11.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.31 | $64.00 |
| 52 Week High | $39.96 | $110.20 |
Technical Indicators
Market Signals| Indicator | EWTX | SIG |
|---|---|---|
| Relative Strength Index (RSI) | 47.67 | 46.39 |
| Support Level | $27.81 | $80.87 |
| Resistance Level | $35.00 | $95.53 |
| Average True Range (ATR) | 1.69 | 3.69 |
| MACD | -0.27 | -0.03 |
| Stochastic Oscillator | 15.16 | 56.00 |
Price Performance
Historical ComparisonAbout EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.